Stocks and Investing Stocks and Investing
Tue, September 24, 2019
Mon, September 23, 2019

Charles Duncan Maintained (ACAD) at Buy with Increased Target to $56 on, Sep 23rd, 2019


Published on 2024-10-26 16:23:08 - WOPRAI, Charles Duncan
  Print publication without navigation


Charles Duncan of Cantor Fitzgerald, Maintained "ACADIA Pharmaceuticals Inc." (ACAD) at Buy with Increased Target from $49 to $56 on, Sep 23rd, 2019.

Charles has made no other calls on ACAD in the last 4 months.



There are 5 other peers that have a rating on ACAD. Out of the 5 peers that are also analyzing ACAD, 1 agrees with Charles's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Paul Matteis of "Stifel" Maintained at Hold with Increased Target to $28 on, Tuesday, September 3rd, 2019


These are the ratings of the 4 analyists that currently disagree with Charles


  • Marc Goodman of "SVB Leerink" Upgraded from Hold to Buy and Increased Target to $50 on, Friday, September 13th, 2019
  • Sumant Kulkarni of "Canaccord Genuity" Upgraded from Hold to Strong Buy on, Tuesday, September 10th, 2019
  • Joseph Stringer of "Needham" Maintained at Strong Buy with Increased Target to $60 on, Monday, September 9th, 2019
  • Danielle Brill of "Raymond James" Reiterated at Strong Buy with Increased Target to $43 on, Friday, May 31st, 2019

Contributing Sources